SCHEMBL7187259

SCHEMBL7187259

NS(=O)(=O)c1cccc(-c2ccc(CBr)cn2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 1/20 0.46
CA1 P00915 7/20 0.43
CA2 P00918 7/20 0.43
CA9 Q16790 5/20 0.43
CA13 Q8N1Q1 3/20 0.43
IKBKB O14920 2/20 0.42
CHUK O15111 1/20 0.42
MAOA P21397 3/20 0.41
KDM1A O60341 1/20 0.41
PTGDR Q13258 1/20 0.40
CA12 O43570 3/20 0.40
CA4 P22748 2/20 0.40
CA7 P43166 2/20 0.40
TTK P33981 1/20 0.40
LRRK2 Q5S007 1/20 0.40
ALOX5AP P20292 1/20 0.39
FAAH O00519 1/20 0.39
CES1 P23141 1/20 0.39
MAOB P27338 3/20 0.39
CA14 Q9ULX7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24668679 0.87 CA1 (0.49) CDK8CA1CA2CA9CA13
SCHEMBL5893217 0.79 CA2 (0.58) CA1CA2CA9CA13MAOA
SCHEMBL27925410 0.75 KIF11 (0.54) CDK8CA1CA2CA9CA13
SCHEMBL21074248 0.74 CDK8 (0.53) CDK8CA1CA2CA9CA13
SCHEMBL29709318 0.74 CDK8 (0.53) CDK8CA1CA2CA9CA13
SCHEMBL2717142 0.73 CYP11B1 (0.59) CYP11B1CYP11B2
SCHEMBL2181186 0.73 CA2 (0.61) CA1CA2CA9CA13CA12
SCHEMBL14075571 0.73 KAT6A (0.53) CDK8CA1CA2CA9CA13
SCHEMBL6837439 0.72 KDM1A (0.74) MAOAKDM1AMAOB
Hydrochloric Acid SCHEMBL10431116 0.72 KAT6A (0.52) CDK8CA1CA2CA9CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO CDK8 4214/4885CA1 4360/4885CA2 2577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.